Medicare will begin covering weight-loss drugs in 2026 for the first time under a pricing agreement announced by the White House, according to a Nov. 6 press release.
The agreements with Eli Lilly and Novo Nordisk apply most-favored-nation pricing to drugs treating obesity, diabetes and related conditions. The monthly Medicare price for Ozempic, Wegovy, Mounjaro and Zepbound will be $245, with patients paying a $50 monthly copay. State Medicaid programs will also have access to the same prices.
What else to know:
- The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month to $350 when purchased through TrumpRx. Zepbound and Orforglipron will drop from $1,086 to an average of $346 per month. If approved, the Wegovy pill will be priced at $150 per month.
- The drugmakers also agreed to discounts on other medicines. Eli Lilly will provide Emgality at $299 per pen and Trulicity at $389 per month. Novo Nordisk will offer insulin products including NovoLog and Tresiba at $35 per month.
- Both companies committed to repatriating foreign revenue, applying MFN pricing to future drugs, and extending pricing to all state Medicaid programs. Novo Nordisk will invest an additional $10 billion in U.S. manufacturing, and Eli Lilly pledged at least $27 billion.
The Trump administration unveiled plans for TrumpRx in September. The federal website is set to launch in 2026 and will offer discounted prescription drugs through partnerships with companies including Mark Cuban’s Cost Plus Drugs, Pfizer and AstraZeneca.
